The global oxygen concentrator market is poised for steady growth, with its valuation expected to climb from USD 4.85 billion in 2024 to USD 8.31 billion by 2033, registering a compound annual growth rate (CAGR) of 6.4% over the forecast period. This expansion is largely fueled by the rising burden of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and sleep apnea, alongside the continuous launch of technologically advanced devices that enhance patient mobility and home‑based care.
According to the latest report by Grand View Research, North America dominated the market in 2024 with a 41.0% revenue share, driven by high disease prevalence and favorable reimbursement policies. In the United States, an aging population requiring long‑term oxygen therapy and legislative efforts such as the proposed Supplemental Oxygen Access Reform (SOAR) Act are further boosting adoption. Meanwhile, the Asia Pacific region is expected to witness the fastest growth through 2033, supported by a rapidly aging demographic, increasing home healthcare focus, and strategic manufacturing agreements in countries like China and Japan.
By product type, fixed oxygen concentrators held the largest share (54.1%) in 2024 due to their higher oxygen output, reliability, and cost‑effectiveness for severe COPD patients. However, portable oxygen concentrators are projected to grow at the fastest CAGR, thanks to lightweight designs, battery operation, and rising demand for patient mobility. In terms of technology, continuous flow devices accounted for the majority of revenue (54.9%), while pulse flow technology is set to expand rapidly, especially in portable units. Home care applications dominated the market in 2024, reflecting a clear shift toward home‑based respiratory care.
The market remains fragmented with intense competition. Recent developments include Inogen’s launch of the Voxi 5 stationary concentrator in June 2025, Caire’s IntenOxy 5 in January 2025, and Oxymed’s P2 portable device in India. However, product recalls pose a notable restraint. In 2024 and 2025, several recalls were issued – including a Class I recall for Jiangsu Jumao’s JMC5A due to overheating and fire hazards, affecting thousands of units, and a recall of approximately 89,000 iGo2 car adapters by Drive DeVilbiss for overheating risks. These safety issues have intensified regulatory scrutiny and impacted supply chains.
Geographically, Europe is evolving rapidly with EU MDR certifications and IoT‑enabled devices, while the Middle East & Africa and Latin America see growing government initiatives and infrastructure investments. Overall, the oxygen concentrator market is poised for sustained growth, driven by technological innovation, home care adoption, and strategic regional expansions – despite ongoing safety and regulatory challenges.